首页> Journal for immunotherapy of cancer> Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jean-Sébastien,Frenel

第一单位： Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France Jean-Sebastien.Frenel@ico.unicancer.fr.

作者： Jean-Sébastien,Frenel ^[1] ; Laurent,Mathiot ^[2] ; Claire,Cropet ^[3] ; Edith,Borcoman ^[4] ; Alice,Hervieu ^[5] ; Elodie,Coquan ^[6] ; Thibault,De La Motte Rouge ^[7] ; Esma,Saada-Bouzid ^[8] ; Renaud,Sabatier ^[9] ; Pernelle,Lavaud ^[10] ; Marta,Jimenez ^[11] ; François,Legrand ^[11] ; Olivia,Le Saux ^[12] ; Emmanuelle,Charafe ^[13] ; Anthony,Gonçalves ^[9]

作者单位： Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France Jean-Sebastien.Frenel@ico.unicancer.fr. ^[1] Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France. ^[2] Department of Biostatistics, Centre Léon Bérard, Lyon, France. ^[3] Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France. ^[4] Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France. ^[5] Department of Medical Oncology, Centre François Baclesse, Caen, France. ^[6] Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. ^[7] Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France. ^[8] Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France. ^[9] Department of Medical Oncology, Gustave Roussy, Villejuif, France.;UNICANCER, Paris, France. ^[10] UNICANCER, Paris, France. ^[11] Department of Medical Oncology, Centre Léon Bérard, Lyon, France. ^[12] Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Biopathology, Institut Paoli-Calmettes, Marseille, France. ^[13]

关键词 Cervical Cancer Chemotherapy Immune Checkpoint Inhibitor